Naveen Yalamanchi
Partner at RTW Investments
New York, New York
Overview
Work Experience
Partner
2015 - Current
Portfolio manager at RTW - $6.5b AUM healthcare investment firm. www.RTWfunds.com
RTW Investments makes investments in forward-thinking healthcare companies.
Dean's Leadership Council
2025
Council Member
2025
Board Observer
2019
Board Observer
2018
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests.
Raised $117,328,098.00 from SightLine Partners, Sectoral Asset Management, RTW Investments, Janus Henderson Investors, HealthQuest Capital and Evidity Health Capital.
Co-Founder and Board Director
2015 - 2025
A clinical stage gene therapy company. Lead indications include: Danon Disease, Fanconi Anemia, Pyruvate Kinase Deficiency. (NASDAQ: RCKT) www.rocketpharma.com
Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.
Raised $891,357,888.00 from RTW Investments, Frazier Healthcare Partners, Sahsen Ventures and Civilization Ventures.
Board Observer
2023 - 2024
Chief Financial Officer
2020 - 2023
Health Sciences Acquisitions Corporation 2 (NASDAQ: HSAQ) completed a business combination with Orchestra Biomed (NASDAQ:OBIO) in Jan 2023.
Chief Financial Officer
2019 - 2019
Health Sciences Acquisitions Corporation (NASDAQ: HSAC) merged with Immunovant Ltd on December 18, 2019. The combined entity is "Immunovant, Inc" (NASDAQ: IMVT).
Board Observer
2017 - 2019
DermTech develops and commercializes qPCR assays for skin samples using adhesive tape biopsy methods.
Raised $259,860,639.00 from HLM Venture Partners, Tech Coast Angels and Western States Investment Group.